Literature DB >> 20227290

Prevention of febrile neutropenia in chemotherapy-treated cancer patients: Pegylated versus standard myeloid colony stimulating factors. Do we have a choice?

Jean Klastersky1, Ahmad Awada.   

Abstract

The pertinent literature on clinical studies comparing the respective value of myeloid colony stimulating factors to pegfilgrastim as a prevention of febrile neutropenia in chemotherapy-treated cancer patients has been reviewed. Pegfilgrastim is definitely not inferior to filgrastim or other myeloid colony stimulating agents with respect to duration of grade IV neutropenia and delivery of full chemotherapy dose on time; several comparative studies indicate a trend to less frequent febrile neutropenia with pegfilgrastim.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20227290     DOI： 10.1016/j.critrevonc.2010.02.005

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN： 1040-8428            Impact factor:   6.312


  7 in total

1.  Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study.

Authors:  Oleg A Gladkov; Anton Buchner; Peter Bias; Udo Müller; Reiner Elsässer
Journal:  Support Care Cancer       Date:  2015-06-20       Impact factor: 3.603

2.  Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study).

Authors:  Pere Gascón; Matti Aapro; Heinz Ludwig; Carsten Bokemeyer; Mario Boccadoro; Matthew Turner; Kris Denhaerynck; Karen MacDonald; Ivo Abraham
Journal:  Support Care Cancer       Date:  2015-08-27       Impact factor: 3.603

3.  Clinical observation of the therapeutic effects of pegylated recombinant human granulocyte colony-stimulating factor in patients with concurrent chemoradiotherapy-induced grade IV neutropenia.

Authors:  Feng-Peng Wu; Jun Wang; Hui Wang; Na Li; Yin Guo; Yun-Jie Cheng; Qing Liu; Xiang-Ran Yang
Journal:  Exp Ther Med       Date:  2014-12-30       Impact factor: 2.447

4.  Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study.

Authors:  Carsten Bokemeyer; Pere Gascón; Matti Aapro; Heinz Ludwig; Mario Boccadoro; Kris Denhaerynck; Michael Gorray; Andriy Krendyukov; Ivo Abraham; Karen MacDonald
Journal:  Support Care Cancer       Date:  2017-01-22       Impact factor: 3.603

5.  Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study).

Authors:  M Aapro; H Ludwig; C Bokemeyer; P Gascón; M Boccadoro; K Denhaerynck; A Krendyukov; M Gorray; K MacDonald; I Abraham
Journal:  Ann Oncol       Date:  2016-11       Impact factor: 32.976

6.  Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.

Authors:  Nadia Harbeck; Oleg Lipatov; Mona Frolova; Dmitry Udovitsa; Eldar Topuzov; Doina Elena Ganea-Motan; Roumen Nakov; Pritibha Singh; Anita Rudy; Kimberly Blackwell
Journal:  Future Oncol       Date:  2016-03-29       Impact factor: 3.404

7.  Systematic Review and Meta-analysis of Short- versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile Neutropenia.

Authors:  Paul Cornes; Pere Gascon; Stephen Chan; Khalid Hameed; Catherine R Mitchell; Polly Field; Mark Latymer; Luiz H Arantes
Journal:  Adv Ther       Date:  2018-10-08       Impact factor: 3.845
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.